Free shipping on all orders over $ 500


Cat. No. M10497

All AbMole products are for research use only, cannot be used for human consumption.

ONO-7475 Structure


Size Price Availability Quantity
5mg USD 170  USD170 In stock
10mg USD 270  USD270 In stock
25mg USD 540  USD540 In stock
50mg USD 850  USD850 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

ONO-7475 is a potent and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. ONO-7475 sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. ONO-7475 combines with Osimertinib provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC).

Mice fed a diet containing ONO-7475 exhibited significantly longer survival and, interestingly, blocked leukemia cell infiltration in the liver. In summary, ONO-7475 effectively kills acute myeloid leukemia cells in vitro and in vivo by mechanisms that involve disruption of diverse survival and proliferation pathways.

Protocol (for reference only)
Cell Experiment
Cell lines MOLM13, MV4;11, HL60, OCI-AML3, MOLM13 luc/gfp cells, MOLM13 p53 shRNA cells, BM-MSC
Preparation method MOLM13 and MV4;11 (FLT3 ITD) and OCI-AML3 (FLT3 WT) cells are incubated with vehicle (0.1% DMSO) or varying doses of ONO-7475 for 48 hours. Viable cell number and apoptosis are measured by flow cytometry.
Concentrations 50-500 nM
Incubation time 24 h, 48 h, 72 h
Animal Experiment
Animal models 4-week old female NSG mice bearing MOLM13 cells
Formulation diet containing 0.004% and 0.013% ONO-7475
Dosages 6 mg/kg, 20 mg/kg
Administration Oral gavage
Chemical Information
Molecular Weight 562.57
Formula C32H26N4O6
CAS Number 1646839-59-9
Solubility (25°C) DMSO 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month

[1] Naoko Okura, et al. Clin Cancer Res. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer

[2] Peter P Ruvolo, et al. Haematologica. Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms

Related TAM Receptor Products

Axl/Mer/CSF1R-IN-2 is a Axl, Mer and CSF1R inhibitor.


AXL-IN-15 is a potent Axl inhibitor with both Ki and IC50 <1 nM.


Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).

DS-1205b free base 

DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo.

Ningetinib Tosylate

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.

Abmole Inhibitor Catalog

Keywords: ONO-7475, ONO7475 supplier, TAM Receptor, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.